Table 2 Patient characteristics of the study group and reference group
Study group in absolut numbers (%) | Reference group in absolut numbers (%) | |
|---|---|---|
Gender | ||
Female | 16 (32) | 45 (35.4) |
Male | 34 (68) | 82 (64.6) |
Age in years [range] | 58,9 [30.3–75.9] | 58.7 [20.3–75.5] |
Median KPS [range] | 90 [60–100] | 90 [70–100] |
MGMT-promoter-status | ||
MGMT-status not determined | 0 (0) | 95 (74.8) |
MGMT-status determined | 50 (100) | 32 (25.2) |
MGMT-promoter methylated | 18 (36) | 14 (43.8) |
MGMT-promoter not methylated | 32 (64) | 18 (56.2) |
Resection status | ||
Gross Total resection | 18 (36) | 58 (45.7) |
Subtotal resection | 30 (60) | 60 (47.2) |
Biopsy | 2 (4) | 9 (7.1) |
Temozolomide therapy | 26 (52) | 127 (100) |
Study medication | 33 (66) | n.e. |
Median delay to RT in days [range] | 35 [18–49] | 27 [5–98] |